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 Pharmaceuticals and personal care products (PPCPs) were monitored in Lake Michigan.
 Fifty-four PPCPs were assessed in surface water and sediment on six dates.
 Many PPCPs, such as metformin, were detected 3.2 km away from the shore.
 Hydrophobic compounds were detected in sediment at concentrations up to 510 ng g1.
 Using a risk quotient, the ecosystem risk was found to be high for many PPCPs.a r t i c l e i n f o
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The monitoring of pharmaceuticals and personal care products (PPCPs) has focused on the distribution in
rivers and small lakes, but data regarding their occurrence and effects in large lake systems, such as the
Great Lakes, are sparse. Wastewater treatment processes have not been optimized to remove inﬂuent
PPCPs and are a major source of PPCPs in the environment. Furthermore, PPCPs are not currently regu-
lated in wastewater efﬂuent. In this experiment we evaluated the concentration, and corresponding risk,
of PPCPs from a wastewater efﬂuent source at varying distances in Lake Michigan. Fifty-four PPCPs and
hormones were assessed on six different dates over a two-year period from surface water and sediment
samples up to 3.2 km from a wastewater treatment plant and at two sites within a harbor. Thirty-two
PPCPs were detected in Lake Michigan and 30 were detected in the sediment, with numerous PPCPs being
detected up to 3.2 km away from the shoreline. The most frequently detected PPCPs in Lake Michigan
were metformin, caffeine, sulfamethoxazole, and triclosan. To determine the ecological risk, the maxi-
mum measured environmental concentrations were compared to the predicted no-effect concentration
and 14 PPCPs were found to be of medium or high ecological risk. The environmental risk of PPCPs in
large lake systems, such as the Great Lakes, has been questioned due to high dilution; however, the con-
centrations found in this study, and their corresponding risk quotient, indicate a signiﬁcant threat by
PPCPs to the health of the Great Lakes, particularly near shore organisms.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Pharmaceutical and personal care products (PPCPs) have been
found in wastewater worldwide (Ternes, 1998; Gomez et al.,
2007; Vieno et al., 2007; Miege et al., 2009; Suarez et al., 2012; Ay-
din and Talini, 2013; Tewari et al., 2013). The level of removal has
been found to vary widely depending on the chemical, the operat-
ing conditions, and the treatment technologies (Miege et al., 2009;
Oulton et al., 2010; Verlicchi et al., 2012; Blair et al., 2013). Vari-
able removal of PPCPs through WWTPs has led to detection of
these compounds in the aquatic environment, albeit mostly in
microgram to nanogram per liter concentrations (Halling-Sorensen
et al., 1998; Kolpin et al., 2002; Cahill et al., 2004; Glassmeyer et al.,
B.D. Blair et al. / Chemosphere 93 (2013) 2116–2123 21172005; Focazio et al., 2008; Snyder, 2008; Kümmerer, 2009; Scheur-
er et al., 2009; Yu and Chu, 2009; Li et al., 2010). Higher pharma-
ceutical concentrations in WWTP efﬂuent have been measured
under certain circumstances, such as WWTPs that receive a sub-
stantial amount of their ﬂow rate from pharmaceutical manufac-
turing (Larsson et al., 2007; Phillips et al., 2010). Research has
shown that certain PPCPs may have an impact on the environment
at the microgram to nanogram per liter concentrations with a
range of potential impacts (Brooks et al., 2003; Fent et al., 2006;
Han et al., 2006; Hernando et al., 2006; Christensen et al., 2009;
Gros et al., 2010; Al Aukidy et al., 2012; Brodin et al., 2013; Tewari
et al., 2013).
The emission of PPCPs into the environment from wastewater
can depend on the wastewater treatment processes, the ﬂow of
the waste stream, and different PPCPs usage patterns that vary
by region and season (Dickenson et al., 2011; Yu et al., 2013). In
an aquatic environment the fate and concentration of PPCPs can
be reliant on the receiving water body ﬂow rate, partitioning to
sediments or biological entities, uptake up by biota, volatilization,
biological degradation, photodegradation, or transformed through
other abiotic mechanisms such as hydrolysis (Yamamoto et al.,
2009). In the Great Lakes, which contains 84% of North America’s
freshwater (USEPA, 2012a), dilution from the source may also be
a major factor in the occurrence and detection of PPCPs in surface
water and sediments.
Limited studies are available that assess PPCPs offshore in large
water bodies due to the expected low levels of PPCPs from dilution
and the complex hydrodynamics in a lake as large as one of the
Great Lakes. Site selection for PPCPs research has focused on bodies
of water that are potentially contaminated from human, industrial,
and agricultural wastewater (Kolpin et al., 2002). Four previous
studies have looked at PPCPs levels in the Great Lakes (Metcalfe
et al., 2003; Wu et al., 2009; Li et al., 2010; Csiszar et al., 2011) with
a wide range of results and they have focused near shore, in har-
bors, and in rivers that are tributaries to the Great Lakes. No previ-
ous studies have assessed PPCPs offshore in Lake Michigan. Lake
Michigan is the sixth largest lake in the world by volume and ﬁfth
by area (Beeton, 2002) and understanding the concentration of
these pollutants in Lake Michigan is critical. Additionally, no previ-
ous studies have assessed the extent of the temporal and spatial
distribution of PPCPs from a large, urban WWTP into the Great
Lakes.
Using a risk quotient (RQ), which is deﬁned as the ratio of the
maximum measured environmental concentration (MEC) to the
predicted no-effect concentration (PNEC), the ecosystem risk from
pollutants can be gauged (Hernando et al., 2006). However, calcu-
lating this ratio can be challenging due to a lack of information
regarding the effects of PPCPs in the environment and difﬁculty
in establishing the PNEC. Researchers have used the RQ to assess
the low levels of PPCPs on ecosystem health with varying results.
Recent studies have found limited ecological risk is expected for
many PPCPs, which may be due to the risk being partially miti-
gated by high dilution (Gros et al., 2010; Al Aukidy et al., 2012;
Yu et al., 2013). Conversely, other studies have found PPCPs of high
or medium risk in secondary efﬂuent, rivers, and small lakes
(Christensen et al., 2009; Valcarcel et al., 2011; Verlicchi et al.,
2012; Tewari et al., 2013). Additionally, levels of concern have been
found in sewage sludge (Yu et al., 2013).
Studies have not been conducted evaluating the occurrence and
risk of PPCPs in Lake Michigan and other studies on the Great Lakes
have assessed a small number of PPCPs. A better understanding of
the occurrence of PPCPs in large water systems, particularly in
areas with substantial urban development, needs further investiga-
tion. The purpose of our study was to assess the risk of 54 PPCPs in
Lake Michigan from varying proximities to a major efﬂuent dis-
charge site and to assess the risk potential to the environment.PPCPs were measured in both surface water and sediment samples
over six dates. The sampling pattern was selected due to the pre-
vailing southern current in this portion of the Lake Michigan basin
(Rao and Schwab, 2007). When possible, a RQ was estimated to
determine which compounds are at a level of concern based on
existing effects data or models.2. Materials and methods
South Shore Water Reclamation Facility (SSWRF) and Jones Is-
land Water Reclamation Facility (JIWRF) service the greater Mil-
waukee, Wisconsin area. Fifty-four PPCPs were measured in Lake
Michigan and compared to the related data on wastewater efﬂuent
from Blair et al. (2013). Both SSWRF and JIWRF uses preliminary
treatment (bar screens/grit channels), primary clariﬁers, activated
sludge treatment and chlorine disinfection. SSWRF has a treatment
capacity of 1135000 m3 d1 (300 MGD (million gallons per day))
with an average ﬂow of approximately 379000 m3 d1 (100
MGD). JIWRF has a treatment capacity of 1457000 m3 d1 (385
MGD) with an average ﬂow of approximately 473000 m3 d1
(125 MGD).
Surface water and sediment samples were collected in Lake
Michigan the day following the sampling at SSWRF. Sampling
was conducted using a Teﬂon Niskin bottle at a depth of 5 m over
sites up to 3.6 km away from the efﬂuent discharge site (Fig. 1).
SSWRF discharges directly into Lake Michigan whereas JIWRF dis-
charges into the Milwaukee Harbor. Field blanks were collected on
each date using distilled water. Grab sediment samples were col-
lected on 5/15/2009 and 4/9/2010. Water and sediment samples
were also collected in the Milwaukee Harbor near JIWRF as a com-
parison site that has lower dilution and potentially higher PPCPs
concentration than the open lake. The ﬁnal efﬂuent was sampled
using a 24-h composite sample as described by Blair et al. (2013).
2.1. PPCPs analysis
PPCPs were extracted and analyzed based upon US EPA Method
1694 (USEPA, 2007a) for pharmaceuticals and US EPA Method
1698 (USEPA, 2007b) for steroids and hormones by using high per-
formance liquid chromatography combined with tandem mass
spectrometry (HPLC/MS/MS) with modiﬁcations as published by
Blair et al. (2013). The PPCPs were selected for this study based
on the EPA methods. Forty-one PPCPs were assessed under EPA
1694 and thirteen hormones were assessed under EPA 1698. Sedi-
ment samples were collected for a subset of the sampling dates
and these data are presented separate from the liquid concentra-
tion. The same 54 PPCPs were assessed in both the water and sed-
iment samples.
2.2. Risk quotient
To determine the risk quotient (RQ) for each compound, the
PNECs were found using the review paper from Verlicchi et al.
(2012) and ECOSAR v1.11 from the US EPA (USEPA, 2012b). When
the values found by Verlicchi et al. (2012) were from an older ver-
sion of ECOSAR, or if the data were not available, the lowest fresh-
water toxicity value from ECOSAR v1.11 was used. The PNEC
selected from these values also included the chronic values from
ECOSAR. An assessment factor (1000) was used to account for sen-
sitivity in other species (Hernando et al., 2006). Using an accepted
range for the RQ, where low risk is below 0.1, medium risk is from
0.1 to 1 and high risk is greater than 1 (Hernando et al., 2006, Ver-
licchi et al., 2012). When a PPCP had a concentration in the blank
above the MQL, this value was subtracted from the maximum con-
centration before the RQ was calculated.
Fig. 1. Lake Michigan and the sampling locations in Lake Michigan near Milwaukee, Wisconsin, USA. Boxes represent the two WWTPs discussed: JIWRF and SSWRF.
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3.1. Surface water concentration
Over six sampling dates, 38 of the 54 compounds were detected
from efﬂuent or Lake Michigan samples. Four compounds were
detected with greater than 50% frequency at all of the sampling
sites in Lake Michigan and the Milwaukee Harbor: metformin
(100%), caffeine (97.6%), sulfamethoxazole (83.3%), and triclosan
(71.4%). Table 1 has the mean and maximum levels from the six
samples dates along with the MDL, MQL, and maximum value
found in the method blanks. The complete data are available in
Supplemental information.
The most widely detected pharmaceutical in our study was the
antidiabetic metformin, which was detected above the minimum
detection limit with 100% frequency in Lake Michigan (Fig. 2a).
Metformin was detected at sites up to 3.2 km away from the shore,
which was unanticipated given the volume of such a large lake sys-
tem and the predominant southern current in this portion of Lake
Michigan. Although metformin is less frequently measured than
other compounds in PPCP studies, we have found, along with oth-
ers, that metformin is prevalent in WWTP inﬂuent at concentra-
tions as high as 129000 ng L1 but the removal efﬁciency ranges
from 41% to over 98% (Scheurer et al., 2009, 2012; Trautwein and
Kümmerer, 2011; Blair et al., 2013; Oosterhuis et al., 2013). The
median value for metformin in Lake Michigan was greater than
100 ng L1, comparable to stream and small lake studies where
metformin has been observed in 4.8% of samples with estimated
levels of 110 ng L1 in the U.S. (Kolpin et al., 2002) and was de-
tected at all of the sites assessed at concentration up to 2000 ng L1
in German rivers (Scheurer et al., 2009, 2012). Given the prevailing
southern water current, the concentration of metformin was ex-
pected to vary at the different sampling sites depending on the
direction from source. Yet average metformin concentrations were
similar to levels found in smaller water bodies and the prevailing
currents did not seem to lead to differences in concentration with
location. Other compounds that followed the same general trend as
metformin were caffeine, paraxanthine, sulfamethoxazole, and
triclosan.
As a contrast to metformin, the anticonvulsant compound car-
bamazepine, shown in Fig. 2b, was detected on all of the samplingdates in the ﬁnal efﬂuent at SSWRF but rarely in Lake Michigan
water or sediment. Carbamazepine has been found to be highly
persistent in wastewater since it is expected to resist biological
degradation (Gomez et al., 2007; Santos et al., 2007; Radjenovic
et al., 2009; Rosal et al., 2010; Blair et al., 2013). However, carbam-
azepine was not detected in the water or sediment samples sur-
rounding SSWRF. Dilution of the wastewater efﬂuent may have
been adequate to reduce the concentration to below the MDL.
However, carbamazepine was detected with 66.7% frequency at
both locations in the Milwaukee harbor at levels above the MDL.
Given the lack of detection of carbamazepine around SSWRF, the
fate of carbamazepine in Lake Michigan is unknown.
Twenty-seven PPCPs were detected at notable levels at the JI
outfall and South gap in the Milwaukee harbor. JI Water Reclama-
tion Facility discharges into the Milwaukee harbor and this is a po-
tential source of these PPCPs, although efﬂuent levels were not
assessed at this WWTP. Additionally, the Milwaukee River also
ﬂows into the harbor and is an additional potential source of the
PPCPs that were detected. As shown in Table 1, the PPCPs concen-
trations in the Milwaukee Harbor were higher overall than the area
surrounding SSWRF. This was used as a reference site as previous
research has shown chronic fecal pollution in the harbor (Newton
et al., 2011). These results agree with other studies assessing har-
bors on the Great Lakes (Metcalfe et al., 2003; Csiszar et al., 2011).
Hormones were not consistently detected above the minimum
detection limit in Lake Michigan. The concentrations of hormones
were low and inconsistent in the ﬁnal efﬂuent at SWWRF which
may be due to the high expected removal from a WWTP through
adsorption, biodegradation, and exposure to chlorine (Joss et al.,
2006; Esperanza et al., 2007; Benotti et al., 2009; Huerta-Fontela
et al., 2011). Given the inconsistent and low levels detected in
the efﬂuent and the high dilution from entering Lake Michigan,
the levels of hormones in the lake from the WWTP would be ex-
pected to be below the detection limit.
3.2. Sediment levels
Thirty compounds were detected in the sediment at levels
above the MDL in Lake Michigan and these compounds are listed
in Table 2. The most commonly detected compounds were: azith-
romycin, clarithromycin, diphenhydramine, metformin, triclosan
Table 1
Concentration of PPCPs at the ﬁnal efﬂuent and at seven locations in Lake Michigan (Below Detection Limit (BDL)).
Field blank Outfall 1.6 km East (1 mi. east) 1.6 km South (1 mi. south) 3.2 km East (2 mi. east) 3.2 km South (2 mi. south) JI outfall South gap
Max MDL MQL Mean, max Mean, max Mean, max Mean, max Mean, max Mean, max Mean, max
ng L1 ng L1 ng L1 ng L1 ng L1 ng L1 ng L1 ng L1 ng L1 ng L1
17,20-Dihydroxyprogesterone BDL 1.4 4.2 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
17-Alpha-estradiol BDL 1.2 3.5 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
17-Beta-estradiol BDL 1.3 3.8 BDL, 1.7* BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, 1.3*
4-Androstene-3,17-dione 4.5 0.5 1.4 97, 580 BDL, 2.0 0.9*, 5.3 3.1, 17 0.8*, 3.5 0.3*, 1.4 BDL, 0.9*
5-Alpha-androstane-3,17-dione BDL 2.3 6.9 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Acetaminophen BDL 2.5 7.5 4.2*, 21 BDL, BDL BDL, BDL BDL, BDL BDL, 2.5* 17, 73 13, 45
Albuterol BDL 1.4 4.2 BDL, BDL BDL, BDL BDL, 5.9 BDL, BDL BDL, BDL BDL 4.3 BDL, BDL
Azithromycin 15.9 3.7 11 BDL, BDL BDL, 12 BDL, 12 BDL, 7.5* BDL, 11 BDL, 22 BDL, 12
Boldenone BDL 1.3 4.0 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Caffeine 62.1 3.1 9.3 44, 110 18, 42 37, 86 21, 35 24, 39 67, 230 71, 190
Carbadox 44.9 3.4 10 7.2*, 20 BDL, 17 12, 49 BDL, 6 6.7*, 33 6.1*, 22 4.2*, 19
Carbamazepine BDL 2.7 8.2 BDL, 6.2* BDL, BDL BDL, BDL BDL, BDL BDL, BDL 15, 38 6.4*, 17
Cimetidine BDL 1.3 3.8 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Ciproﬂoxacin BDL 3.3 9.9 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Clarithromycin BDL 3.2 9.6 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Codeine BDL 3.6 11 BDL, 11 BDL, 8.7* BDL, 9.2* BDL, 5.4* BDL, 7.2* 4.4*, 11 5.3*, 15
Cotinine BDL 3.5 11 BDL, 7.4* BDL, 6.5* BDL, 5* BDL, 6.1* BDL, 11 BDL, 20 3.5*, 21
Digoxigenin BDL 4.4 13.2 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Diltiazem 5.4 3.5 10 BDL, 7.9* BDL, 5.5* BDL, 7.8* BDL, BDL BDL, BDL 6.3, 21 BDL, 10
Diphenhydramine 4.2 3.6 11 4.1*, 14 BDL, 6.6* BDL, 9.2* BDL, 4.9* BDL, 6.7* 10*, 43 3.6*, 12
Estriol BDL 2 6.1 BDL, BDL BDL, 3.9* BDL, BDL BDL, 5.0* BDL, BDL BDL, BDL BDL, 4.9*
Estrone BDL 2.2 6.7 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, 3.4* BDL, BDL BDL, BDL
Fluoxetine BDL 3.5 11 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 8.2*, 49 10*, 62
Gemﬁbrozil BDL 1.6 4.8 9.1, 42 BDL, BDL 1.6*, 4.5* BDL, BDL 3.1*, 19 14, 36 13, 43
Ibuprofen BDL 4.7 14 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Lincomycin BDL 3.1 9.3 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Lomeﬂoxacin BDL 4.7 14.2 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Melengestrol BDL 1.3 4 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Melengestrol Acetate BDL 0.6 1.7 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Metformin 35.5 0.5 1.5 1200, 3800 240, 820 270, 840 120, 160 110, 160 4100, 9200 1200, 2400
Miconazole BDL 2.7 8.1 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Naproxen BDL 1 2.9 4.9, 19 BDL, BDL 2.5*, 15 BDL, BDL BDL, BDL 8.4, 31 4.8, 18
Norﬂoxacin BDL 5.1 15.3 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Oﬂoxacin BDL 3.9 12 10*, 61 BDL, 21 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Oxacillin BDL 2.5 7.4 BDL, BDL BDL, BDL BDL, BDL 2.9*, 17 BDL, BDL BDL, BDL BDL, BDL
Paraxanthine 11.6 6.1 18 6.3*, 23 BDL, 9.7* 11*, 39 BDL, BDL BDL, 8.7* 15*, 57 15*, 45
Progesterone 17.8 0.7 2 2.0, 11 1.0*, 4.9 1.5*, 8.7 15, 88 2.6, 13 BDL, BDL BDL, BDL
Ranitidine BDL 0.9 2.6 BDL, BDL BDL, 3.7 BDL, BDL BDL, BDL BDL, BDL 5.4, 27 BDL, BDL
Roxithromycin 5.5 4.3 13 BDL, 8.7* BDL, BDL BDL, 7.5* 4.5*, 15 6.5*, 39 BDL, 9.2* BDL, BDL
Saraﬂoxacin BDL 5.4 16 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Sulfachloropyridazine BDL 4.1 12 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Sulfadiazine BDL 2.8 8.5 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, 3.8* BDL, BDL
Sulfadimethoxine BDL 2.4 7.1 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Sulfamerazine BDL 2.1 6.2 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, 3.6*
Sulfamethazine BDL 4.0 12 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Sulfamethizole BDL 4.2 13 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Sulfamethoxazole BDL 4.1 12 6.9*, 14 BDL, 6.2* 5.1,* 7.0* BDL, 7.3* 4.5*, 10* 29, 77 16, 30
Sulfanilamide BDL 2.9 8.6 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL 6.3*, 20 BDL, BDL
Sulfathiazole BDL 2.6 8 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Testosterone 12.4 1.1 3.2 2.2*, 13 BDL, 4.5 1.5*, 9.1 6.4, 38 1.4*, 7.0 BDL, BDL BDL, BDL
Thiabendazole BDL 1.8 5.3 BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL BDL, BDL
Triclocarban BDL 0.5 1.4 2.6, 16 BDL, BDL BDL, BDL BDL, BDL BDL, BDL 3.9, 9.9 BDL, BDL
Triclosan 5.4 0.5 1.6 9.9, 41 0.8*, 2.1 3.0, 16 2.7, 7.4 1.4*, 6.5 7.7, 24 5.0, 11
Trimethoprim BDL 3.4 10 BDL, 3.4* BDL, BDL BDL, 6.0* BDL, BDL BDL, BDL 17, 52 6.9*, 13
* Value above MDL, but below MQL.
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Fig. 2. Concentration of metformin (a) and carbamazepine (b) in wastewater efﬂuent and in Lake Michigan on six dates.
2120 B.D. Blair et al. / Chemosphere 93 (2013) 2116–2123and triclocarban. Of these compounds, all of them were regularly
detected in the ﬁnal efﬂuent, with the exception of the macrolide
antibiotic clarithromycin, which was detected only once. Given
the low occurrence in the ﬁnal efﬂuent and across the stages of
SSWRF (Blair et al., 2013), the regular and widespread occurrence
of clarithromycin in sediment is of interest. Azithromycin and
clarithromycin were found to have limited sorption to sludge in
WWTPs (Verlicchi et al., 2012) therefore their detection in sedi-
ment needs further investigation. Triclosan and triclocarban were
detected in Lake Michigan sediment due to their regular occur-
rence in efﬂuent and their known hydrophobic characteristics
(Loranzo et al., 2013). Additionally, the detection of metformin
and diphenhydramine in Lake Michigan sediment is notable.
Other PPCPs detected in the sediment cannot be clearly contrib-
uted to the efﬂuent from SSWRF. For example, thiabendazole, a
fungicide, was detected at low levels in the ﬁnal efﬂuent, but
was only located in the sediment at the 1.6 km east and 3.2 km east
sampling locations and was not detected in the surface water. The
detection at these locations implies the potential source is fromland runoff, not discharged from SSWRF. With detection only at
the eastern locations, not the southern locations, the source may
be from area north of the WWTP. Signiﬁcant agricultural develop-
ments are not present in the area north of SSWRF, but a residential
area that includes many parks and golf courses are a possible
source of this fungicide.
3.3. Ecological risk quotient
Overall, a total of twenty-four compounds were detected in the
ﬁnal efﬂuent or Lake Michigan at a level of medium or high risk. As
shown in Fig. 3, fourteen compounds were detected in Lake Mich-
igan itself with high or medium risk. Metformin, the most wide-
spread compound, did not correspond with high or medium risk
at the concentrations detected; however, this may be due to the
lack of predictive toxicity data on the chronic effects of this com-
pound. When comparing the ﬁnal efﬂuent RQs to the values in Lake
Michigan, many compounds drop below the threshold to medium
or low risk after the compound is discharged from the WWTP, such
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Fig. 3. Risk quotient for 14 PPCPs in wastewater efﬂuent and in Lake Michigan (RQ > 1 is high risk, RQ from 0.1 to 1 is medium risk, and RQ < 0.1 is low risk).
Table 2
PPCPs levels in sediment from Lake Michigan (compounds listed in Table 1 that were not detected above the MDL in the sediment samples are omitted from this table).
SS
outfall
1.6 km East (1 mi.
east)
1.6 km South (1 mi.
south)
3.2 km East (2 mi.
east)
3.2 km South (2 mi.
south)
JI
outfall
South
gap
MDL MQL Mean Mean Mean Mean Mean Mean Mean
ng g1 ng g1 ng g1 ng g1 ng g1 ng g1 ng g1 ng g1 ng g1
Acetaminophen 2.5 7.5 BDL 18 29 BDL BDL BDL 29
Azithromycin 3.7 11 490 16 72 19 25 59 350
Caffeine 3.1 9.3 25 BDL 24 30 14 4.2* BDL
Carbadox 3.4 10 BDL BDL BDL BDL BDL BDL 14
Ciproﬂoxacin 3.3 9.9 42 7.7* 9.0* 46 52 43 BDL
Clarithromycin 3.2 9.6 33 28 130 5* 120 90 BDL
Codeine 3.6 11 BDL BDL BDL BDL BDL 4* BDL
Cotinine 3.5 11 8.0* BDL BDL BDL BDL 39 BDL
Digoxigenin 4.4 13 BDL BDL BDL BDL BDL 4.9* 9.2*
Diltiazem 3.5 10 4.0* BDL BDL BDL BDL 5.2* 3.9*
Diphenhydramine 3.6 11 81 13 43 7.3* 82 150 160
Enroﬂoxacin 1.4 4.1 BDL BDL BDL 6.6 BDL BDL BDL
Erythromycin 9.9 30 BDL BDL BDL BDL BDL 25* BDL
Flumequine 5.2 16 BDL BDL BDL 6.9* BDL BDL 6.0*
Fluoxetine 3.5 11 7.6* BDL BDL BDL BDL 20 12
Ibrupoven 4.7 14 BDL BDL 8.8* BDL BDL BDL No Data
Lincomycin 3.1 9.3 BDL BDL BDL BDL BDL BDL 5⁄
Metformin 0.51 1.5 50 43 3.8 16 2.3 59 140
Miconazole 2.7 8.1 7.6 BDL BDL BDL BDL 3.7* 8.4
Naproxen 0.97 2.9 4.8 1.0* BDL BDL BDL 2.6* No Data
Norﬂoxacin 5.1 15 BDL BDL BDL 12* 36 BDL BDL
Oﬂoxacin 3.9 12 4.3* BDL BDL 7.7* BDL BDL 7.3*
Oxacillin 2.5 7.4 BDL BDL BDL BDL 2.8* BDL 9.1
Paraxanthine 6.1 18 BDL BDL BDL BDL BDL BDL 15*
Roxithromycin 4.3 13 28 BDL 31 BDL 44 71 BDL
Saraﬂoxacin 5.4 16 BDL BDL BDL 9.9* BDL BDL BDL
Thiabendazole 1.8 5.3 BDL 230 BDL 68 BDL BDL BDL
Triclocarban 0.48 1.4 170 4.5 33 BDL 11 510 No Data
Triclosan 0.53 1.6 37 18 22 26 12 150 No Data
Tylosin 3.5 11 9.4* 12 3.9* BDL 14 20 BDL
* Value above MDL, but below MQL.
B.D. Blair et al. / Chemosphere 93 (2013) 2116–2123 2121as gemﬁbrozil and diltiazem. However, dilution is not sufﬁcient to
reduce the risk of all compounds to below the high and medium
threshold, even at a distance of 3.2 km from shore, such as for sul-
famethoxazole and codeine.4. Conclusion
The detection of such a large number of PPCPs with high or
medium risk in the Great Lakes is novel and of concern. The area
surrounding the SS outfall and the sites within the Milwaukee Har-
bor are important as they are near locations for ﬁsh spawning andaquatic organisms, such as perch, can be found congregating
around the efﬂuent pipes of SSWRF and are exposed to efﬂuent
concentration with little dilution. Knowing that PPCPs can impact
the behavior of aquatic organisms (Brodin et al., 2013; Brooks
et al., 2003) leads to the conclusion that the endpoints used to
assess the PNEC values for PPCPs may not properly address the
ecological impacts and further testing is needed to identify the
PPCPs of greatest concern. Additionally, the RQ may also underes-
timate risk due to potential mixture effects of PPCPs with similar
mechanisms of action that may be additive in their impact. Reli-
ance on a model such as ECOSAR is useful for identiﬁcation of
2122 B.D. Blair et al. / Chemosphere 93 (2013) 2116–2123PPCPs that warrant further research, but these models are not a
replacement for experimental tests to determine the full ecological
impacts from PPCPs.
PPCPs were frequently detected in the water and sediments at
the ng L1 level, including sites 3.2 km from shore in Lake Michigan
at concentrations that are estimated to cause environmental con-
cern. At the concentrations detected, medium or high risk was
associated with twenty-four compounds in the ﬁnal efﬂuent, and
fourteen were found to be of medium or high risk in Lake Michigan.
The most frequently detected PPCPs were metformin, caffeine, sul-
famethoxazole, and triclosan. Given the widespread detection of
PPCPs, these pollutants are not ephemeral and pose an environ-
mental risk to the sixth largest lake in the world. Therefore, high
dilution is not adequate to mitigate the risk from this cocktail of
PPCPs and the potential ecological risk for large lake systems is
much higher than previously understood.
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